Related Experiment Video
Updated: May 29, 2026
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers
Roberta Sanfilippo1, Federica Grosso, Robin L Jones
1Cancer Medicine Department, Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. roberta.sanfilippo@istitutotumori.mi.it
Background:
Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma.
Patients And Methods:
A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed.
Results:
Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively.
Conclusions:
Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.
Insights
Trabectedin shows efficacy in treating metastatic uterine leiomyosarcoma, offering a palliative option for patients with advanced disease. This study evaluated its effectiveness in a specific patient subgroup.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic uterine leiomyosarcoma has limited treatment options.
- Trabectedin is an established treatment for advanced soft tissue sarcomas resistant to conventional chemotherapy.
- This study focuses on trabectedin's efficacy in uterine leiomyosarcoma.
Purpose of the Study:
- To evaluate the efficacy of trabectedin in patients with metastatic uterine leiomyosarcoma.
- To assess treatment response, survival rates, and adverse events associated with trabectedin therapy.
Main Methods:
- Retrospective analysis of 66 patients with uterine leiomyosarcoma treated between 2000 and 2010.
- Data collected from two reference sarcoma centers.
- Assessment of radiological response, progression-free survival (PFS), overall survival (OS), and adverse events.
Main Results:
- 16% of patients achieved partial response, and 35% had stable disease.
- Median PFS was 3.3 months (95% CI 2-5).
- Progression-free rates at 3 and 6 months were 53% and 33%, respectively.
Conclusions:
- Trabectedin is a viable therapeutic option for palliative treatment of metastatic uterine leiomyosarcoma.
- The drug demonstrates activity in a patient population with limited therapeutic choices.
- Further research may explore optimal use in this specific sarcoma subtype.
